All Immuno-oncology articles – Page 2
-
BusinessPfizer gambles on $14bn Medivation deal
Cancer specialist likely just one target in hunt for marketed drugs to offset patent expiries
-
BusinessAmgen and Advaxis partner on immuno-oncology
Deal covers rights to system for building cancer therapies specific to a patient’s own tumours
-
BusinessCelgene and Jounce team up against cancer
Firms promise next-generation immuno-oncology as existing drugs rack up successes
-
BusinessJuno CAR-T trial suspended after patient deaths
Immunotherapy study restarted with amended pre-treatment protocol
-
BusinessNovartis partners with Xencor for cancer antibodies
Deal deepens Novartis’s focus on immuno-oncology
-
BusinessCancer deals spread
AbbVie nabs antibody specialist Stemcentrx, while Sanofi pursues Medivation
-
BusinessRoche sketches out Blueprint collaboration
Drug discovery startup will contribute to cancer immunotherapy projects aimed at kinase enzymes
-
Business
AstraZeneca to buy Acerta for blood cancer drug
Deal will strengthen AstraZeneca’s immunotherapy offering
-
-
BusinessViral cancer therapy approved in the US
T-Vec is the first approved oncolytic virus, but its limited treatment scope means it is unlikely to become a blockbuster
-
Business
BMS agrees $1.7bn immuno-oncology collaboration
Deal strengthens cancer antibody alliance with Five Prime Therapeutics
-
BusinessMerger fever sweeps pharma
The life sciences sector has been gripped by a mergers and acquisition frenzy, and it looks set to continue. But what does it mean for the industry?
-
Business
Grabbing slices of the immuno-oncology pie
Another spate of immuno-oncology dealmaking adds to fervour in pharma’s ‘hottest space’
-
FeaturePharma queues up for checkpoint inhibitor collaborations
Combinations of different firms’ drugs seek to reap immuno-oncology’s benefits
-
BusinessCompanies clamour for CAR-T
Engineered immune cell therapies show promise in early cancer trials, prompting firms to compete for a foothold in the field
-
BusinessBMS sues executive for joining rival company
Bristol-Myers Squibb’s lawsuit against its former immuno-oncology chief who left to work for AstraZeneca has implications for biopharma industry
-
Business
BMS bolsters immuno-oncology with pair of deals
Firm will acquire Flexus Biosciences and collaborate with Rigel
-
Business
Clinical collaborations drive cancer immunotherapy
Companies race to pair up chemotherapy drugs with immune system-boosting antibodies to greatest effect in trials
-
Business
First of a new breed of anticancer antibodies approved in Japan
Ono claims Opdivo is the first anti-PD1 treatment in the world
-
BusinessPharma vies to unleash immune system power on cancer
Immuno-oncological drugs look set to earn billions and significantly lengthen patients’ lives
- Previous Page
- Page1
- Page2
- Next Page